Most platforms that touch your quality records never read them. They store the record, version it, route it for signature, retain it for the inspector. None of that is analysis. Analysis is the moment a system reads a deviation and decides whether the investigation satisfies 21 CFR 211.192. Five categories of platform sit near this problem. Only one does it in real time.
"Real-time" is the most overloaded word in the QMS market. It is used to describe dashboard refresh frequency, alert latency, workflow state updates, and content evaluation against regulations. These are different capabilities. Understanding which category a platform belongs to is the difference between an evaluation that lands and one that ends in a misaligned procurement.
The Two Things "Real-Time" Can Mean
Real-time analysis splits cleanly into two architecturally distinct capabilities.
Real-time workflow state monitoring tracks where a quality record sits in its lifecycle. Was the deviation routed within 24 hours? Was the CAPA approved? Are there overdue investigations? Every modern QMS does this, and most "real-time dashboards" deliver this.
Real-time content evaluation reads the substance of the record and assesses whether it satisfies a specific regulation. Does the deviation root cause demonstrate scientific rationale under 21 CFR 211.192? Does the CAPA address the root cause it follows? Does the validation protocol cover the documentation requirements of EU GMP Annex 11? This is a different capability.
Both are legitimate uses of the term. Buyer evaluations go off the rails when the two are treated as substitutes.
The Five Categories, and What Each One Actually Does
| Category | Workflow State | Content Evaluation | Framework Coverage |
|---|---|---|---|
| Quality Management Systems | Yes | Limited | QMS process compliance |
| Regulatory Information Management | Yes (submissions) | No | Submission lifecycle |
| Regulatory monitoring databases | No | No | Changes in the regulations |
| Document-AI tools | No | Single document type | Narrow (e.g., protocols) |
| AI regulatory intelligence | Via QMS data | Yes | 150+ frameworks |
1. Quality Management Systems
Veeva Vault QMS, MasterControl, TrackWise, and similar platforms own the workflow. Document control, version history, approval chains, training records, CAPA tracking. The QMS tells you a deviation exists and who signed it. It does not tell you whether the investigation behind that deviation is adequate under 211.192. The QMS is the system of record. It is not the system that reads the record.
Modern QMS platforms increasingly add risk scoring, recurrence checks, and AI-assisted features. These help. They operate primarily on metadata and workflow signals rather than the full content of investigation narratives against the regulatory framework.
2. Regulatory Information Management Systems
RIMS track submission status, registrations, and health-authority correspondence. They answer "where is this filing in its lifecycle." They do not answer "does the content of this submission satisfy the framework." A different problem, a complementary system, often confused with QMS in early evaluations.
3. Regulatory Monitoring Databases
These track what changed in the regulations themselves: new FDA guidances, agency announcements, framework revisions. They are alert-based and passive. They tell you the standard moved. They do not check your records against it.
4. Niche Document-AI Tools
A growing category applies AI to one document type: protocol review, submission drafting, template consistency. Genuine content analysis, but bounded to a single domain. They do not read across the lifecycle, and a systemic pattern that spans preclinical, manufacturing, and post-market never surfaces because no single tool sees all three.
5. AI Regulatory Intelligence Platforms
This is the category that performs real-time analysis of quality-record content against regulatory standards. The platform sits over the QMS through API integration, with no data migration, and continuously evaluates records as they are created or changed. A deviation gets read against investigation-adequacy requirements the moment it is logged. An OOS result gets cross-referenced against the frameworks it implicates.
Clinplex AI operates in this category, evaluating records against 150+ regulatory frameworks across all five lifecycle domains, from preclinical GLP through clinical GCP, CMC manufacturing under 21 CFR 211, regulatory submissions, and post-market pharmacovigilance. Integration with Veeva Vault QMS, MasterControl, and TrackWise is API-based, preserving the QMS as the validated system of record under 21 CFR Part 11.
The test for any "real-time" claim: ask the platform to name the specific regulation a given quality record was evaluated against, and show the gap. A storage system cannot answer that. A workflow dashboard cannot answer that. An analysis layer answers it as its core function. The test takes one record and five minutes.
The Reframe: Storage Is Not Analysis
The reason most real-time compliance claims fall apart on inspection: real-time logging is common, and real-time analysis is rare. Your QMS can timestamp a record the instant it is filed. That is logging. Reading that record against 211.192 and flagging an inadequate investigation before it becomes a 483 observation, that is analysis. The first is a database feature. The second is a different category of product.
The architectural distinction matters because it determines what you actually need to buy. If the gap is workflow visibility, the answer is a better QMS or a better dashboard inside the QMS you have. If the gap is content evaluation against regulations, no QMS configuration closes it. The capability lives in a different layer.
Where This Leaves a Buyer
Most quality organizations already own a QMS and will keep it. The QMS is the system of record and should stay that way. The open question is whether anything reads the records the QMS holds. If the answer is "we sample 20 records at a mock audit twice a year," there is no real-time analysis happening. There is periodic sampling.
Continuous analysis evaluates all 200 records, not a 10% sample, and does it as the records change rather than two months before an inspection. That gap, between the records you store and the analysis nobody runs against them continuously, is the entire reason the fifth category exists.
For a biotech or pharma firm evaluating real-time platforms, the practical sequence is: identify which of the two real-time definitions applies to your gap, evaluate the corresponding category, and resist the temptation to treat workflow dashboards and content evaluation as substitutes. They solve different problems and they coexist in the same compliance stack.
See Content Evaluation Against Your QMS Data
Upload a quality record from your existing Veeva, MasterControl, or TrackWise deployment. Get content evaluation against 150+ frameworks, with the specific 21 CFR or ICH citations that apply. No QMS migration required.
Run Free Analysis →